AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyNot reportedTrial registry
Study of BRIUMVI® in Participants with RMS
A study was conducted to evaluate the safety and effectiveness of BRIUMVI® (ublituximab-xiiy) among 2000 participants with relapsing multiple sclerosis (RMS), following them for up to 96 weeks. The study aimed to gain insights into the treatment experience in a real-world setting.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
Understanding the real-world safety and effectiveness of BRIUMVI® is important for guiding treatment options for individuals with RMS.
What this does not prove
No results have been posted, and details about planned enrollment and endpoints are not findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 2000 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Yes
- Research areas
- Not classified
Original sources
Supporting passages (7)
subjectsThe study population will include participants with RMS who are receiving BRIUMVI® (ublituximab-xiiy).
sample size"count": 2000, "type": "ESTIMATED"
regulatory approval"isFdaRegulatedDrug": true
primary endpoint"measure": "Annualized Relapse Rate (ARR)"
follow up"timeFrame": "Up to Week 96"
findings"briefSummary": "The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting"
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.